A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)

Investigational New Drugs

Volumn 29, Issue 5, 2011, Pages 1038-1044

  Viéitez, José María ^a   Valladares, Manuel ^b   Peláez, Ignacio ^c   De Sande González, Luis ^d   García Foncillas, Jesús ^e   García López, José Luis ^f   García Girón, Carlos ^g   Reboredo, Margarita ^b   Bovio, Humberto ^h   Lacave, Angel Jiménez ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b HOSPITAL JUAN CANALEJO   (Spain)

^c HOSPITAL DE CABUEÑES   (Spain)

^d HOSPITAL DE LEÓN   (Spain)

^e UNIVERSITY CLINIC OF NAVARRA   (Spain)

^f HOSPITAL RAMÓN Y CAJAL   (Spain)

^g HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^h ASTRAZENECA   (United Kingdom)

Author keywords

Colorectal cancer; Gefitinib; Phase II; Raltitrexed; Randomized; Second line

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHORYLATED EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHORYLATED MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHORYLATED PROTEIN KINASE B; PLACEBO; PROTEIN KINASE B; RALTITREXED; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE; THIOPHENE DERIVATIVE; TUMOR MARKER;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; HUMAN TISSUE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TISSUE SECTION; ADOLESCENT; CLINICAL TRIAL; COLORECTAL TUMOR; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DEMOGRAPHY; METABOLISM; MIDDLE AGED; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEMOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; QUINAZOLINES; SURVIVAL ANALYSIS; THIOPHENES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84856077157     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9400-z     Document Type: Article

References (30)

1. Cappuzzo F, Finocchiaro G, Rossi E et al (2008) EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 19:717-723
2. Macarulla T, Ramos FJ, Capdevila J et al (2006) Novel targets for anticancer treatment development in colorectal cancer. Clin Colorectal Cancer 6:265-272
3. Mead GM (1996) Raltitrexed, a new drug for advanced colorectal cancer. Lancet 347:1568-1569
4. Zalcberg JR, Cunningham D, Van Cutsem E et al (1996) ZD1694: a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group. J Clin Oncol 14:716-721
5. Aparicio J, Vicent JM, Maestu I et al (2003) Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer. Ann Oncol 14:1121-1125
6. Cunningham D (1998) Mature results from three large controlled studies with raltitrexed ('Tomudex'). Br J Cancer 77:15-21
7. Cunningham D, Zalcberg JR, Rath U et al (1995) 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group. Eur J Cancer 31 A: 1945-1954
8. Scheithauer W, Kornek GV, Raderer M et al (2002) Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer. J Clin Oncol 20:165-172
9. Scheithauer W, Kornek GV, Schuell B et al (2001) Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy. Ann Oncol 12:709-714
10. Jonker DJ, O'Callaghan CJ, Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048
11. Maiello E, Giuliani F, Gebbia V et al (2007) Cetuximab: clinical results in colorectal cancer. Ann Oncol 18:8-10
12. Messersmith WA, Hidalgo M (2007) Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one? Clin Cancer Res 13:4664-4666
13. Saltz LB, Lenz HJ, Kindler HL et al (2007) Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 5:4557-4561
14. Van Cutsem E (2007) Integration of the anti-EGFR agent panitumumab into clinical practice in metastatic colorectal cancer. Clin Adv Hematol Oncol 5:611-613
15. Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664
16. Van Cutsem E, Verslype C, Beale P et al (2008) A phase Ib doseescalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients. Ann Oncol 19:332-339
17. Capdevila J, Mendez G, Macarulla T et al (2007) New approaches in systemic treatment of advanced colorectal cancer: the molecular targets era. Expert Rev Anticancer Ther 7:1027-1041
18. Rothenberg ML, LaFleur B, Levy DE et al (2005) Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol 23:9265-9274
19. Townsley CA, Major P, Siu LL et al (2006) Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br J Cancer 94:1136-1143
20. Kuo T, Cho CD, Halsey J et al (2005) Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J Clin Oncol 23:5613-5619
21. Ciardiello F, Caputo R, Bianco R et al (2000) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptorselective tyrosine kinase inhibitor. Clin Cancer Res 6:2053-2063
22. Van Schaeybroeck S, Karaiskou-McCaul A, Kelly D et al (2005) Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res 11:7480-7489
23. Monti M, Motta S (2007) Clinical management of cutaneous toxicity of anti-EGFR agents. Int J Biol Markers 22:S53-S61
24. Wacker B, Nagrani T, Weinberg J et al (2007) Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 13:3913-3921
25. Chau I, Cunningham D, Hickish T et al (2007) Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecannaive advanced colorectal cancer: a phase I-II study. Ann Oncol 18:730-737
26. Veronese ML, Sun W, Giantonio B et al (2005) A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. Br J Cancer 92:1846-1849
27. Rougier P, Van Cutsem E, Bajetta E et al (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407-1412
28. Viéitez JM, Carrasco J, Esteban E et al (2003) Irinotecan in the treatment of advanced colorectal cancer in patients pretreated with Fluorouracil-based chemotherapy: a study to determine recommendable therapeutic dosage. Am J Clin Oncol 26:107-111
29. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67:2643-2648
30. De Roock W, Piessevaux H, De Schutter J et al (2008) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19:508-515